Kineta News June 17, 2022Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit >> June 17, 2022Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies SummitJune 7, 2022Puget Sound Business Journal: Seattle biotech Kineta to go public in reverse merger deal with Yumanity Therapeutics >> June 7, 2022Puget Sound Business Journal: Seattle biotech Kineta to go public in reverse merger deal with Yumanity TherapeuticsJune 6, 2022GeekWire: Seattle biotech Kineta will go public in deal with neurosciences company Yumanity Therapeutics >> June 6, 2022GeekWire: Seattle biotech Kineta will go public in deal with neurosciences company Yumanity Therapeutics
